Awareness, attitudes, and experiences of patients taking antiretrovirals towards adverse drug reactions at a public health facility in KwaZulu-Natal.
Loading...
Date
2020
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Adverse drug reactions (ADRs) are undesirable side effects that occur even when a drug is
administered at the proper dose and correctly for an appropriate indication. Given the high
prevalence of Human Immuno-deficiency Virus (HIV) in South Africa, more than 3 million people
are reported to be taking antiretrovirals (ARVs). Therefore, patients taking ARVs may also be
taking other medicines due to other existing diseases such as diabetes, hypertension, and
tuberculosis. The concurrent use of other medicines with ARVs may increase the potential of
ADRs, snowballing to increased numbers of hospitalisations and contributing to mortality rates.
The study investigated awareness, attitudes, and experiences of ADRs among patients taking
ARVs. This was a descriptive cross-sectional study using a questionnaire that contained closeended
questions to which patients responded. The study was conducted at a selected public hospital
in KwaZulu-Natal. Questionnaires were available in both English and isiZulu and were hand
delivered to patients. Ethical approval was obtained prior to commencement of this study. The
participants were recruited by a random systematic selection by choosing every second participant.
Both verbal and written consents were obtained before handing out questionnaires for participation.
Statistical Package for Social Sciences (SPSS®) version of 25 was used to capture and analyse
data. Categorical measurements were summarised using frequencies and proportions. Out of 200
questionnaires, a total of 174 patients responded, which delivered an 87% response rate. Of the 174
respondents, 55% (n=96) were females and 45% (n=78) were males. About 8% (n=13) of
respondents were aware of ADRs, 55% (n=94) of drug–drug interactions and 12% (n=20) had
reported ADRs. About 13% (n=22) respondents reported having hypertension, 7% (n=4)
respondents reported diabetes and 1% (n=2) respondents reported tuberculosis. Almost 65%
(n=114) respondents took the fixed drug combination, 17% (n=30) respondents took lamivudine
and zidovudine combination, and 2.3% (n=4) respondents took ritonavir and atazanavir
combinations. About 5% (n=8) respondents experienced vomiting, 1.7% (n=3) of respondents
experienced diarrhoea and 1.1% (n=2) respondents experienced rashes. Most patients on ARVs and
anti-TB medicines can experience reduced hearing or deafness, particularly in patients using
medicines such as Kanamycin. Most medicines metabolised by CYP450, such as rifampicin and
lopinavir/ritonavir combination, where rifampicin lowers ritonavir blood serum levels therefore
requiring a boost of ritonavir. Patients should therefore be made aware of ADRs of ARVs,
particularly those that may arise due to drug-drug interactions among the patients that have coexisting
diseases. Patients should also be counselled to report ADRs, to obtain the ADR form,
complete it and ensure they submit the ADR reports the healthcare professionals as well as the
pharmacovigilance centre. The awareness of ADRs among patients taking ARVs could be
improved by providing quality training and in-depth counselling of the patients during their visit to
the hospital in order to ensure optimal therapy and patients safety.
Description
Masters Degree. University of KwaZulu-Natal, Durban.